Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 4, 2013, Pages 383-389

  Antoun, Sami ^a   Borget, Isabelle ^b   Lanoy, Emilie ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Gustave Roussy ^*  (France)

Author keywords

Body composition; Chemotherapy toxicity; Sarcopenia; Skeletal muscle density; Skeletal muscle mass

Indexed keywords

ANTINEOPLASTIC AGENT;

BODY COMPOSITION; BODY MASS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; NEOPLASM; PROGNOSIS; REVIEW; RISK ASSESSMENT; SARCOPENIA;

ANTINEOPLASTIC AGENTS; BODY COMPOSITION; BODY MASS INDEX; HUMANS; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SARCOPENIA;

EID: 84887933453     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000011     Document Type: Review

References (30)

1. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34:503-509.
2. Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004; 90:1905-1911.
3. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12:489-495.
4. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48:303-332; Review.
5. Baracos VE, Reiman T, Mourtzakis M, et al. Body composition in patients with nonsmall cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010; 91:1133S-1137S.
6. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31:1539-1547.
7. Tan BHL, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15:6973-6979.
8. Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated with post operative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012; 107:931-937.
9. Antoun S, Birdsell L, Sawyer MB, et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advances renal cell carcinoma: results from a placebo-controlled study. J Clin Onc 2010; 28:1054-1060.
10. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9:629-635.
11. Aslani A, Smith RC, Allen BJ, et al. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000; 88:796-803.
12. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13:3264-3268.
13. Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33:997-1006.
14. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004; 97:2333-2338.
15. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15:2920-2926.
16. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21:1594-1598.
17. Gusella M, Toso S, Ferrazzi E, et al. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 2002; 54:131-139.
18. Nawaratne S, Brien JE, Seeman E, et al. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 1998; 46:447-452.
19. Thompson PA, Rosner GL, Matthay KK, et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 2009; 64:243-251.
20. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012; 7:e37563.
21. Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab 2013; 98:2401-2408.
22. Sabel MS, Lee J, Cai S, et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 2011; 18:3579-3585.
23. Peng PD, van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts shortterm outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB 2011; 13:439-446.
24. Cosquéric G, Sebag A, Ducolombier C, et al. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr 2006; 96:895-901.
25. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10:166-173.
26. Alexandre J, Rey E, Girre V, et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 2007; 18:168-172.
27. Goodpaster BH, Kelley DE, Thaete FL, et al. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 2000; 89:104-110.
28. Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis in metastatic renal cell carcinoma treated by target therapies. Cancer 2013; 119:3377-3384.
29. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19:1613-1618.
30. Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013; 108:1034-1041.